MRI Interventions, a commercial stage medical technology company, today said its ClearPoint® Neuro Intervention System will be featured as a platform for MRI-guided drug delivery to the brain at the 2013 Annual Targeted Drug Delivery Conference in San Francisco on Sunday, May 5.
ClearPoint will be showcased in three presentations to be given during the session, "Amazing Things on the Horizon for Pain and Neurologic Disease":
The first presentation, "Gene Therapy and Other Approaches to Neurodegenerative Disease," will be conducted by Krys Bankiewicz, M.D., PhD, vice chair and professor in the Department of Neurosurgery and Director of the NeuroTherapeutics Delivery Center at the University of California, San Francisco. Dr. Bankiewicz will highlight an upcoming clinical trial in which the ClearPoint System will be used to guide convection-enhanced delivery of AAV2-AADC in real time under MRI-guidance into the putamen of patients with Parkinson's disease.
Russell Lonser, M.D., chair of the Department of Neurological Surgery at the Ohio State Wexner Medical Center, will follow with his presentation titled "Convection Enhanced Intraparenchymal Drug Delivery," which will discuss imaging features associated with convective drug delivery in the brain stem using the ClearPoint System.
Manish Aghi, M.D., PhD, associate professor in Residence of Neurological Surgery and Principal Investigator at the Brain Tumor Research Center at University of California, San Francisco, will conclude the ClearPoint presentation by demonstrating data on the real-time MRI-guided delivery of Toca 511 directly into malignant brain tumors using the ClearPoint System the treatment of recurrent high grade glioma, including glioblastoma multiforme (GBM, Grade IV glioma), the most common and aggressive form of brain cancer.
For more information, visit MRIinterventions.com
Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net